Adial Pharmaceuticals, Inc. Financing Cash Flow
Adial Pharmaceuticals, Inc. (ADIL) reported Financing Cash Flow of $25.52 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-14
- Adial Pharmaceuticals, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $25.21M, a 375.78% increase year-over-year.
- Adial Pharmaceuticals, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $315.28K, a 522.50% increase year-over-year.
- Adial Pharmaceuticals, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $2.60M.
- Adial Pharmaceuticals, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $524.80K, a 85.46% decline year-over-year.
- Adial Pharmaceuticals, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $8.47M, a 8.00% increase from fiscal 2024.
- Adial Pharmaceuticals, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $7.85M, a 89.87% increase from fiscal 2023.
- Adial Pharmaceuticals, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $4.13M, a 54.72% decline from fiscal 2022.
- Adial Pharmaceuticals, Inc. net cash provided by (used in) financing activities for fiscal 2022 was $9.13M, a 33.12% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 6 month as first filed | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $25.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $25.52M 10-Q · filed 2026-08-14 | $28.12M derived: sum of 3 quarters · filed 2026-08-14 | $28.65M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2026-03-31 | $315.28K 10-Q · filed 2026-05-08 | $2.91M derived: sum of 2 quarters · filed 2026-05-08 | $3.44M derived: sum of 3 quarters · filed 2026-05-08 | $8.74M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-12-31 | $2.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $3.12M derived: sum of 2 quarters · filed 2026-03-05 | $8.42M derived: sum of 3 quarters · filed 2026-08-14 | $8.47M 10-K · filed 2026-03-05 | |
| 2025-09-30 | $524.80K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $5.82M derived: sum of 2 quarters · filed 2026-08-14 | $5.87M 10-Q · filed 2025-11-13 | $5.87M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-06-30 | $5.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $5.35M 10-Q · filed 2026-08-14 | $5.35M 10-Q · filed 2025-08-13 | $5.35M derived: sum of 3 quarters · filed 2026-08-14 | $8.96M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $50.65K 10-Q · filed 2026-05-08 | $50.65K derived: sum of 2 quarters · filed 2026-05-08 | $3.66M derived: sum of 3 quarters · filed 2026-05-08 | $4.07M derived: sum of 4 quarters · filed 2026-05-08 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $3.61M derived: sum of 2 quarters · filed 2026-03-05 | $4.02M derived: sum of 3 quarters · filed 2026-03-05 | $7.85M 10-K · filed 2026-03-05 | |
| 2024-09-30 | $3.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $4.02M derived: sum of 2 quarters · filed 2025-11-13 | $7.85M 10-Q · filed 2025-11-13 | $11.23M derived: sum of 4 quarters · filed 2025-11-13 | |
| 2024-06-30 | $411.09K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $4.24M 10-Q · filed 2025-08-13 | $7.62M derived: sum of 3 quarters · filed 2025-08-13 | $7.76M derived: sum of 4 quarters · filed 2025-08-13 | |
| 2024-03-31 | $3.82M 10-Q · filed 2025-05-14 | $7.21M derived: sum of 2 quarters · filed 2025-05-14 | $7.35M derived: sum of 3 quarters · filed 2025-05-14 | $7.35M derived: sum of 4 quarters · filed 2025-05-14 | |
| 2023-12-31 | $3.38M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | $3.52M derived: sum of 2 quarters · filed 2025-03-04 | $3.52M derived: sum of 3 quarters · filed 2025-03-04 | $4.13M 10-K · filed 2025-03-04 | |
| 2023-09-30 | $138.67K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $138.73K derived: sum of 2 quarters · filed 2024-11-13 | $748.34K 10-Q · filed 2024-11-13 | $748.34K derived: sum of 4 quarters · filed 2024-11-13 | |
| 2023-06-30 | $58.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $609.67K 10-Q · filed 2024-08-13 | $609.67K derived: sum of 3 quarters · filed 2024-08-13 | $609.67K derived: sum of 4 quarters · filed 2024-08-13 | |
| 2023-03-31 | $609.61K 10-Q · filed 2023-05-12 | $609.61K derived: sum of 2 quarters · filed 2024-04-01 | $609.61K derived: sum of 3 quarters · filed 2024-04-01 | $611.48K derived: sum of 4 quarters · filed 2024-04-01 | |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $0.00 derived: sum of 2 quarters · filed 2024-04-01 | $1.86K derived: sum of 3 quarters · filed 2024-04-01 | $9.13M 10-K · filed 2024-04-01 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q/A 6 month · filed 2023-11-14 | $1.86K derived: sum of 2 quarters · filed 2023-11-14 | $9.13M 10-Q · filed 2023-11-14 | $10.38M derived: sum of 4 quarters · filed 2023-11-14 | |
| 2022-06-30 | $1.86K derived: 10-Q/A 6 month − 10-Q 3 month · filed 2023-10-30 | $9.13M 10-Q/A · filed 2023-10-30 | $10.38M derived: sum of 3 quarters · filed 2023-10-30 | $15.88M derived: sum of 4 quarters · filed 2023-10-30 | |
| 2022-03-31 | $9.12M 10-Q · filed 2023-05-12 | $10.38M derived: sum of 2 quarters · filed 2023-05-12 | $15.88M derived: sum of 3 quarters · filed 2023-05-12 | $18.69M derived: sum of 4 quarters · filed 2023-05-12 | |
| 2021-12-31 | $1.25M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $6.76M derived: sum of 2 quarters · filed 2023-03-30 | $9.56M derived: sum of 3 quarters · filed 2023-03-30 | $13.64M 10-K · filed 2023-03-30 | |
| 2021-09-30 | $5.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $8.31M derived: sum of 2 quarters · filed 2022-11-14 | $12.39M 10-Q · filed 2022-11-14 | $12.39M derived: sum of 4 quarters · filed 2022-11-14 | |
| 2021-06-30 | $2.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $6.89M 10-Q · filed 2022-08-15 | $6.89M derived: sum of 3 quarters · filed 2022-08-15 | $7.84M derived: sum of 4 quarters · filed 2022-08-15 | |
| 2021-03-31 | $4.08M 10-Q · filed 2022-05-16 | $4.08M derived: sum of 2 quarters · filed 2022-05-16 | $5.03M derived: sum of 3 quarters · filed 2022-05-16 | ||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $950.01K derived: sum of 2 quarters · filed 2022-03-28 | $5.61M 10-K · filed 2022-03-28 | ||
| 2020-09-30 | $950.01K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $5.61M 10-Q · filed 2021-11-15 | |||
| 2020-06-30 | $4.66M 10-Q · filed 2021-08-12 | ||||
| 2019-12-31 | $109.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-22 | $287.00 derived: sum of 2 quarters · filed 2021-03-22 | $313.00 derived: sum of 3 quarters · filed 2021-03-22 | $9.25M 10-K · filed 2021-03-22 | |
| 2019-09-30 | $178.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-13 | $204.00 derived: sum of 2 quarters · filed 2020-11-13 | $9.25M 10-Q · filed 2020-11-13 | $9.40M derived: sum of 4 quarters · filed 2020-11-13 | |
| 2019-06-30 | $26.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-13 | $9.25M 10-Q · filed 2020-08-13 | $9.40M derived: sum of 3 quarters · filed 2020-08-13 | $15.06M derived: sum of 4 quarters · filed 2020-08-13 | |
| 2019-03-31 | $9.25M 10-Q · filed 2020-05-14 | $9.40M derived: sum of 2 quarters · filed 2020-05-14 | $15.06M derived: sum of 3 quarters · filed 2020-05-14 | $15.35M derived: sum of 4 quarters · filed 2020-05-14 | |
| 2018-12-31 | $156.25K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-20 | $5.81M derived: sum of 2 quarters · filed 2020-03-20 | $6.10M derived: sum of 3 quarters · filed 2020-03-20 | $6.35M 10-K · filed 2020-03-20 | |
| 2018-09-30 | $5.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | $5.94M derived: sum of 2 quarters · filed 2019-11-14 | $6.19M 10-Q · filed 2019-11-14 | $6.29M derived: sum of 4 quarters · filed 2019-11-14 | |
| 2018-06-30 | $285.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-13 | $535.00K 10-Q · filed 2019-08-13 | $635.00K derived: sum of 3 quarters · filed 2019-08-13 | $675.00K derived: sum of 4 quarters · filed 2019-08-13 | |
| 2018-03-31 | $250.00K 10-Q · filed 2019-05-13 | $350.00K derived: sum of 2 quarters · filed 2019-05-13 | $390.00K derived: sum of 3 quarters · filed 2019-05-13 | ||
| 2017-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-19 | $140.00K derived: sum of 2 quarters · filed 2019-02-19 | $390.00K 10-K · filed 2019-02-19 | ||
| 2017-09-30 | $40.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14 | $290.00K 10-Q · filed 2018-11-14 | |||
| 2017-06-30 | $250.00K 10-Q · filed 2018-09-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |